Avadel Pharmaceuticals (AVDL) Financials

$9.13 +0.25 (+2.82%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$9.10 -0.03 (-0.32%)

As of 05/23/2025 04:35 PM Eastern

Annual Income Statements for Avadel Pharmaceuticals

This table shows Avadel Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-49	-160	-137
Consolidated Net Income / (Loss)	-49	-160	-137
Net Income / (Loss) Continuing Operations	-49	-160	-137
Total Pre-Tax Income	-49	-161	-111
Total Operating Income	-42	-138	-99
Total Gross Profit	154	27	0.00
Total Revenue	169	28	0.00
Operating Revenue	169	28	0.00
Total Cost of Revenue	15	0.85	0.00
Operating Cost of Revenue	15	0.85	0.00
Total Operating Expenses	196	165	99
Selling, General & Admin Expense	181	152	75
Research & Development Expense	15	13	21
Restructuring Charge	0.00	0.00	3.35
Total Other Income / (Expense), net	-6.68	-23	-13
Interest Expense	11	23	12
Interest & Investment Income	4.15	0.09	-0.54
Income Tax Expense	-0.25	-0.50	26
Basic Earnings per Share	($0.51)	($2.00)	($2.29)
Weighted Average Basic Shares Outstanding	95.14M	80.17M	60.09M
Diluted Earnings per Share	($0.51)	($2.00)	($2.29)
Weighted Average Diluted Shares Outstanding	95.14M	80.17M	60.09M
Weighted Average Basic & Diluted Shares Outstanding	96.63M	90.58M	64.48M

This table shows Avadel Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-4.92	-5.04	-2.63	-14	-27	-29	-36	-64	-31	-27	-20
Consolidated Net Income / (Loss)	-4.92	-5.04	-2.63	-14	-27	-29	-36	-64	-31	-27	-20
Net Income / (Loss) Continuing Operations	-4.92	-5.04	-2.63	-14	-27	-29	-36	-64	-31	-27	-20
Total Pre-Tax Income	-4.84	-4.96	-2.54	-14	-27	-29	-36	-64	-31	-27	-20
Total Operating Income	-3.00	-3.30	-0.33	-13	-26	-25	-35	-50	-28	-23	-17
Total Gross Profit	47	46	44	39	26	19	6.90	1.46	0.00	-	0.00
Total Revenue	53	50	50	42	27	19	7.01	1.50	0.00	-	0.00
Operating Revenue	53	50	50	42	27	19	7.01	1.50	0.00	-	0.00
Total Cost of Revenue	5.58	4.81	6.16	2.79	1.52	0.69	0.12	0.04	0.00	-	0.00
Operating Cost of Revenue	5.58	4.81	6.16	2.79	1.52	0.69	0.12	0.04	0.00	-	0.00
Total Operating Expenses	50	49	44	51	52	44	42	51	28	23	17
Selling, General & Admin Expense	46	45	40	47	49	41	39	47	24	17	14
Research & Development Expense	4.35	4.27	3.80	4.05	3.07	2.36	2.85	4.22	3.83	6.24	2.93
Total Other Income / (Expense), net	-1.84	-1.67	-2.21	-1.59	-1.21	-3.99	-1.08	-15	-3.07	-4.33	-3.12
Interest Expense	2.24	2.70	2.82	2.72	2.59	2.35	1.98	15	3.26	3.26	3.56
Interest & Investment Income	0.40	1.04	0.61	1.13	1.38	-1.63	0.90	0.62	0.19	-1.07	0.45
Income Tax Expense	0.08	0.08	0.09	-0.51	0.09	-0.10	0.09	0.09	-0.58	0.09	0.07
Basic Earnings per Share	($0.05)	($0.04)	($0.03)	($0.14)	($0.30)	($0.28)	($0.41)	($0.83)	($0.48)	($0.44)	($0.33)
Weighted Average Basic Shares Outstanding	96.60M	95.14M	96.30M	96.15M	91.69M	80.17M	89.38M	77.25M	63.89M	60.09M	60.20M
Diluted Earnings per Share	($0.05)	($0.04)	($0.03)	($0.14)	($0.30)	($0.28)	($0.41)	($0.83)	($0.48)	($0.44)	($0.33)
Weighted Average Diluted Shares Outstanding	96.60M	95.14M	96.30M	96.15M	91.69M	80.17M	89.38M	77.25M	63.89M	60.09M	60.20M
Weighted Average Basic & Diluted Shares Outstanding	96.74M	96.63M	96.36M	96.27M	96.12M	90.58M	89.81M	89.37M	76.77M	64.48M	61.78M

This table details how cash moves in and out of Avadel Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	20	-43	23
Net Cash From Operating Activities	-47	-129	-70
Net Cash From Continuing Operating Activities	-47	-129	-70
Net Income / (Loss) Continuing Operations	-49	-160	-137
Consolidated Net Income / (Loss)	-49	-160	-137
Depreciation Expense	2.68	1.77	1.49
Amortization Expense	0.00	2.80	6.05
Non-Cash Adjustments To Reconcile Net Income	20	29	7.01
Changes in Operating Assets and Liabilities, net	-21	-1.74	53
Net Cash From Investing Activities	52	-50	80
Net Cash From Continuing Investing Activities	52	-50	80
Purchase of Property, Plant & Equipment	0.00	0.00	-0.72
Purchase of Investments	-276	-237	-3.41
Sale and/or Maturity of Investments	328	187	84
Net Cash From Financing Activities	16	135	15
Net Cash From Continuing Financing Activities	16	135	15
Repayment of Debt	0.00	-43	-13
Issuance of Debt	0.00	30	0.00
Issuance of Common Equity	16	148	28
Other Net Changes in Cash	-0.64	0.46	-0.66
Cash Interest Paid	7.18	5.25	9.66
Cash Income Taxes Paid	0.00	0.00	-29

This table details how cash moves in and out of Avadel Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	5.00	23	-0.27	-6.95	4.63	-21	1.83	-33	9.41	13	6.59
Net Cash From Operating Activities	-8.23	7.87	-6.89	-18	-30	-28	-38	-32	-30	-15	-6.80
Net Cash From Continuing Operating Activities	-8.23	7.87	-6.44	-19	-30	-28	-38	-32	-30	-15	-6.80
Net Income / (Loss) Continuing Operations	-4.92	-5.04	-2.63	-14	-27	-29	-36	-64	-31	-27	-20
Consolidated Net Income / (Loss)	-4.92	-5.04	-2.63	-14	-27	-29	-36	-64	-31	-27	-20
Depreciation Expense	0.83	0.67	1.04	0.44	0.54	-0.02	0.60	0.60	0.59	0.59	0.40
Non-Cash Adjustments To Reconcile Net Income	4.18	4.13	5.41	5.46	5.39	3.52	3.13	21	1.52	1.93	1.92
Changes in Operating Assets and Liabilities, net	-8.32	8.12	-10	-11	-8.29	-2.74	-6.01	10	-3.43	7.67	9.10
Net Cash From Investing Activities	12	15	4.93	11	21	28	9.82	-93	5.07	23	2.52
Net Cash From Continuing Investing Activities	12	15	4.93	11	21	28	9.82	-93	5.07	23	2.52
Purchase of Investments	-5.49	-14	-86	-78	-98	-34	-90	-103	-10	-1.08	-0.13
Sale and/or Maturity of Investments	18	29	91	89	119	62	100	10	15	24	3.37
Net Cash From Financing Activities	0.69	0.88	1.18	0.72	13	-21	30	92	34	6.62	11
Net Cash From Continuing Financing Activities	0.69	0.88	1.18	0.72	13	-21	30	92	34	6.62	11
Issuance of Common Equity	0.69	0.88	1.18	0.72	13	0.05	0.46	136	12	15	11
Effect of Exchange Rate Changes	0.22	-	0.52	-0.03	-0.25	-	-0.23	-0.02	0.14	-	0.15
Cash Interest Paid	1.89	3.88	1.56	1.02	0.73	0.73	-	1.47	3.05	-	3.21

This table presents Avadel Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	164	165	133
Total Current Assets	134	134	101
Cash & Equivalents	51	31	74
Short-Term Investments	22	74	23
Accounts Receivable	34	12	0.00
Inventories, net	20	10	0.00
Prepaid Expenses	6.04	6.61	2.10
Plant, Property, & Equipment, net	0.45	0.59	0.84
Total Noncurrent Assets	30	30	31
Goodwill	17	17	17
Other Noncurrent Operating Assets	13	13	13
Total Liabilities & Shareholders' Equity	164	165	133
Total Liabilities	90	77	154
Total Current Liabilities	49	37	56
Accounts Payable	7.33	11	7.89
Accrued Expenses	41	24	7.33
Other Current Liabilities	0.86	1.20	2.90
Total Noncurrent Liabilities	42	40	98
Other Noncurrent Operating Liabilities	42	40	6.52
Total Equity & Noncontrolling Interests	74	88	-21
Total Preferred & Common Equity	74	88	-21
Preferred Stock	0.00	0.05	0.01
Total Common Equity	74	88	-21
Common Stock	893	856	590
Retained Earnings	-794	-745	-585
Accumulated Other Comprehensive Income / (Loss)	-25	-23	-26

This table presents Avadel Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	168	158	158	168	203	201	141	146
Total Current Assets	139	127	126	136	172	171	109	113
Cash & Equivalents	56	29	29	36	52	50	83	61
Short-Term Investments	10	37	43	53	101	111	18	46
Accounts Receivable	42	37	33	23	6.24	1.78	-	-
Inventories, net	20	16	13	12	5.29	1.44	-	-
Prepaid Expenses	11	8.25	6.78	11	6.35	6.53	6.26	4.67
Plant, Property, & Equipment, net	0.31	0.47	0.48	0.53	0.65	0.72	0.78	0.90
Total Noncurrent Assets	28	31	31	31	30	29	30	32
Goodwill	17	17	17	17	17	17	17	17
Other Noncurrent Operating Assets	12	14	14	14	13	12	12	14
Total Liabilities & Shareholders' Equity	168	158	158	168	203	201	141	146
Total Liabilities	94	84	87	90	93	58	179	158
Total Current Liabilities	51	43	45	48	54	52	79	42
Accounts Payable	9.12	7.92	9.79	19	13	12	10	2.48
Accrued Expenses	41	34	34	28	18	18	7.68	7.97
Other Current Liabilities	0.90	0.96	1.11	1.21	1.65	1.28	41	4.77
Total Noncurrent Liabilities	43	41	43	42	39	6.28	100	117
Other Noncurrent Operating Liabilities	43	41	43	42	39	6.28	6.41	6.75
Total Equity & Noncontrolling Interests	74	75	70	78	110	143	-38	-12
Total Preferred & Common Equity	74	75	70	78	110	143	-38	-12
Preferred Stock	0.00	0.00	0.00	0.00	0.05	0.05	0.01	0.01
Total Common Equity	74	75	70	78	110	143	-38	-12
Common Stock	898	888	881	875	853	850	604	573
Retained Earnings	-799	-789	-787	-773	-717	-680	-616	-558
Accumulated Other Comprehensive Income / (Loss)	-24	-24	-24	-24	-26	-26	-26	-28

This table displays calculated financial ratios and metrics derived from Avadel Pharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	504.79%	0.00%	0.00%
EBITDA Growth	70.20%	-46.44%	-9.02%
EBIT Growth	69.24%	-39.86%	-15.21%
NOPAT Growth	69.24%	-39.86%	-15.21%
Net Income Growth	69.53%	-16.59%	-77.77%
EPS Growth	74.50%	12.66%	-73.48%
Operating Cash Flow Growth	63.50%	-82.79%	9.06%
Free Cash Flow Firm Growth	30.17%	-292.11%	68.26%
Invested Capital Growth	100.41%	-249.27%	-81.65%
Revenue Q/Q Growth	22.41%	228.59%	0.00%
EBITDA Q/Q Growth	35.95%	-3.39%	2.23%
EBIT Q/Q Growth	33.75%	-1.37%	0.10%
NOPAT Q/Q Growth	33.75%	-1.37%	0.10%
Net Income Q/Q Growth	32.72%	-0.84%	-3.89%
EPS Q/Q Growth	32.00%	7.41%	-2.69%
Operating Cash Flow Q/Q Growth	43.36%	-10.93%	9.22%
Free Cash Flow Firm Q/Q Growth	37.59%	-20.44%	34.88%
Invested Capital Q/Q Growth	-99.20%	20.47%	-32.80%
Profitability Metrics	-	-	-
Gross Margin	90.97%	96.97%	0.00%
EBITDA Margin	-23.49%	-476.65%	0.00%
Operating Margin	-25.07%	-492.97%	0.00%
EBIT Margin	-25.07%	-492.97%	0.00%
Profit (Net Income) Margin	-28.87%	-573.17%	0.00%
Tax Burden Percent	99.50%	99.69%	123.35%
Interest Burden Percent	115.76%	116.63%	113.07%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-60.44%	-481.35%	-481.49%
Cash Return on Invested Capital (CROIC)	-66,369.44%	0.00%	-45.86%
Operating Return on Assets (OROA)	-25.78%	-92.68%	0.00%
Return on Assets (ROA)	-29.69%	-107.75%	0.00%
Return on Common Equity (ROCE)	-60.42%	-480.94%	-481.41%
Return on Equity Simple (ROE_SIMPLE)	-66.13%	-182.67%	650.10%
Net Operating Profit after Tax (NOPAT)	-30	-96	-69
NOPAT Margin	-17.55%	-345.08%	0.00%
Net Nonoperating Expense Percent (NNEP)	-21.41%	-176.37%	762.53%
Return On Investment Capital (ROIC_SIMPLE)	-40.19%	-109.98%	-63.80%
Cost of Revenue to Revenue	9.03%	3.03%	0.00%
SG&A Expenses to Revenue	107.05%	542.52%	0.00%
R&D to Revenue	8.99%	47.42%	0.00%
Operating Expenses to Revenue	116.04%	589.94%	0.00%
Earnings before Interest and Taxes (EBIT)	-42	-138	-99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-40	-133	-91
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	13.71	0.00	0.00
Price to Tangible Book Value (P/TBV)	17.76	0.00	0.00
Price to Revenue (P/Rev)	5.99	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	13,225.11	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.55	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	-6.11
Long-Term Debt to Equity	0.00	0.00	-4.33
Financial Leverage	-1.11	-1.09	0.31
Leverage Ratio	2.04	4.47	6.66
Compound Leverage Factor	2.36	5.21	7.53
Debt to Total Capital	0.00%	0.00%	119.55%
Short-Term Debt to Total Capital	0.00%	0.00%	34.83%
Long-Term Debt to Total Capital	0.00%	0.00%	84.72%
Preferred Equity to Total Capital	0.00%	0.06%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	99.94%	-19.56%
Debt to EBITDA	0.00	0.00	-1.42
Net Debt to EBITDA	0.00	0.00	-0.36
Long-Term Debt to EBITDA	0.00	0.00	-1.01
Debt to NOPAT	0.00	0.00	-1.87
Net Debt to NOPAT	0.00	0.00	-0.48
Long-Term Debt to NOPAT	0.00	0.00	-1.33
Altman Z-Score	0.75	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.03%	0.09%	0.02%
Liquidity Ratios	-	-	-
Current Ratio	2.75	3.64	1.81
Quick Ratio	2.21	3.18	1.73
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-47	-67	-17
Operating Cash Flow to CapEx	0.00%	0.00%	-9,818.99%
Free Cash Flow to Firm to Interest Expense	-4.35	-2.93	-1.39
Operating Cash Flow to Interest Expense	-4.33	-5.58	-5.70
Operating Cash Flow Less CapEx to Interest Expense	-4.33	-5.58	-5.75
Efficiency Ratios	-	-	-
Asset Turnover	1.03	0.19	0.00
Accounts Receivable Turnover	7.32	0.00	0.00
Inventory Turnover	1.00	0.00	0.00
Fixed Asset Turnover	325.85	39.27	0.00
Accounts Payable Turnover	1.63	0.09	0.00
Days Sales Outstanding (DSO)	49.86	0.00	0.00
Days Inventory Outstanding (DIO)	366.48	0.00	0.00
Days Payable Outstanding (DPO)	224.12	4,168.38	0.00
Cash Conversion Cycle (CCC)	192.22	-4,168.38	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	0.07	-17	12
Invested Capital Turnover	-19.55	-9.75	0.00
Increase / (Decrease) in Invested Capital	17	-29	-52
Enterprise Value (EV)	939	0.00	0.00
Market Capitalization	1,013	0.00	0.00
Book Value per Share	$0.77	$0.98	($0.34)
Tangible Book Value per Share	$0.59	$0.79	($0.61)
Total Capital	74	88	108
Total Debt	0.00	0.00	129
Total Long-Term Debt	0.00	0.00	92
Net Debt	-74	-105	33
Capital Expenditures (CapEx)	0.00	0.00	0.72
Debt-free, Cash-free Net Working Capital (DFCFNWC)	12	-7.76	-14
Debt-free Net Working Capital (DFNWC)	85	97	83
Net Working Capital (NWC)	85	97	45
Net Nonoperating Expense (NNE)	19	64	68
Net Nonoperating Obligations (NNO)	-74	-105	33
Total Depreciation and Amortization (D&A)	2.68	4.56	7.55
Debt-free, Cash-free Net Working Capital to Revenue	6.86%	-27.77%	0.00%
Debt-free Net Working Capital to Revenue	50.48%	348.13%	0.00%
Net Working Capital to Revenue	50.48%	348.13%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.51)	($2.00)	($2.29)
Adjusted Weighted Average Basic Shares Outstanding	95.14M	80.17M	60.09M
Adjusted Diluted Earnings per Share	($0.51)	($2.00)	($2.29)
Adjusted Weighted Average Diluted Shares Outstanding	95.14M	80.17M	60.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	96.63M	90.58M	64.48M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-96	-67
Normalized NOPAT Margin	-17.55%	-345.08%	0.00%
Pre Tax Income Margin	-29.02%	-574.96%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-3.92	-5.99	-7.99
NOPAT to Interest Expense	-2.74	-4.19	-5.59
EBIT Less CapEx to Interest Expense	-3.92	-5.99	-8.04
NOPAT Less CapEx to Interest Expense	-2.74	-4.19	-5.65
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Avadel Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	93.21%	159.14%	613.22%	2,674.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	91.46%	89.45%	102.07%	74.55%	1.33%	-21.27%	-133.45%	-74.10%	7.91%	9.18%	41.79%
EBIT Growth	88.47%	86.76%	99.07%	74.28%	8.00%	-8.08%	-107.02%	-65.48%	1.15%	0.42%	33.91%
NOPAT Growth	88.47%	86.76%	99.07%	74.28%	8.00%	-8.08%	-107.02%	-65.48%	1.15%	0.42%	33.91%
Net Income Growth	82.01%	82.48%	92.76%	78.55%	11.18%	-4.87%	-80.06%	-1.56%	-16.50%	-23.09%	8.44%
EPS Growth	83.33%	85.71%	92.68%	83.13%	37.50%	36.36%	-24.24%	22.43%	-6.67%	-15.79%	13.16%
Operating Cash Flow Growth	72.29%	128.09%	81.98%	43.21%	1.75%	-82.41%	-461.90%	-127.27%	11.20%	31.72%	67.97%
Free Cash Flow Firm Growth	39.58%	-270.55%	-312.07%	62.19%	-141.52%	-67.52%	-52.59%	-213.58%	472.35%	438.25%	373.42%
Invested Capital Growth	172.91%	100.41%	140.54%	-130.97%	59.09%	-249.27%	-226.13%	-86.85%	-134.16%	-81.65%	-71.11%
Revenue Q/Q Growth	4.17%	0.77%	20.53%	52.71%	39.71%	177.35%	368.85%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	17.20%	-471.19%	105.75%	51.74%	-2.31%	27.10%	29.31%	-87.15%	-25.75%	-40.34%	47.28%
EBIT Q/Q Growth	8.95%	-907.95%	97.43%	51.06%	-4.56%	29.08%	29.13%	-75.07%	-22.83%	-35.84%	43.35%
NOPAT Q/Q Growth	8.95%	-907.95%	97.43%	51.06%	-4.56%	29.08%	29.13%	-75.07%	-22.83%	-35.84%	43.35%
Net Income Q/Q Growth	2.44%	-92.11%	81.01%	49.45%	5.02%	20.64%	43.70%	-109.30%	-12.15%	-36.26%	68.25%
EPS Q/Q Growth	-25.00%	-33.33%	78.57%	53.33%	-7.14%	31.71%	50.60%	-72.92%	-9.09%	-33.33%	69.16%
Operating Cash Flow Q/Q Growth	-204.56%	214.27%	62.11%	38.78%	-5.98%	26.68%	-19.37%	-5.92%	-96.75%	-125.87%	51.72%
Free Cash Flow Firm Q/Q Growth	-1.73%	36.14%	-620.64%	87.09%	-387.17%	-20.60%	228.50%	-114.17%	124.61%	15.91%	207.81%
Invested Capital Q/Q Growth	10,584.51%	-99.20%	909.51%	89.49%	40.10%	20.47%	-718.26%	113.89%	-318.55%	-32.80%	-35.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.38%	90.45%	87.70%	93.28%	94.40%	96.44%	98.33%	97.59%	0.00%	0.00%	0.00%
EBITDA Margin	-4.14%	-5.21%	1.42%	-29.65%	-93.80%	-128.09%	-487.30%	-3,232.15%	0.00%	0.00%	0.00%
Operating Margin	-5.72%	-6.54%	-0.65%	-30.70%	-95.79%	-128.00%	-500.57%	-3,311.56%	0.00%	0.00%	0.00%
EBIT Margin	-5.72%	-6.54%	-0.65%	-30.70%	-95.79%	-128.00%	-500.57%	-3,311.56%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-9.37%	-10.00%	-5.25%	-33.30%	-100.60%	-147.98%	-517.17%	-4,306.95%	0.00%	0.00%	0.00%
Tax Burden Percent	101.61%	101.63%	103.47%	96.45%	100.34%	99.65%	100.25%	100.14%	98.15%	100.31%	100.35%
Interest Burden Percent	161.35%	150.55%	775.84%	112.48%	104.66%	116.01%	103.06%	129.88%	110.83%	118.78%	118.37%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-1,676.62%	0.00%	0.00%	0.00%	-228.19%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-1,671.97%	0.00%	0.00%	0.00%	-173.83%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	1,652.87%	0.00%	0.00%	0.00%	136.05%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-34.65%	-60.44%	-78.54%	-23.75%	-779.92%	-481.35%	-325.33%	-92.14%	-1,662.06%	-481.49%	-305.87%
Cash Return on Invested Capital (CROIC)	-415.85%	-66,369.44%	-852.54%	0.00%	0.00%	0.00%	0.00%	-389.25%	0.00%	-45.86%	-68.41%
Operating Return on Assets (OROA)	-6.62%	-6.72%	-0.50%	-16.30%	-34.23%	-24.06%	-24.42%	-27.61%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-10.85%	-10.29%	-4.01%	-17.68%	-35.95%	-27.82%	-25.23%	-35.90%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-34.65%	-60.42%	-78.52%	-23.74%	-779.82%	-480.94%	-325.14%	-92.10%	-1,661.09%	-481.41%	-305.84%
Return on Equity Simple (ROE_SIMPLE)	-35.66%	0.00%	-97.20%	-151.13%	-200.08%	0.00%	-144.30%	-99.73%	371.60%	0.00%	1,063.63%
Net Operating Profit after Tax (NOPAT)	-2.10	-2.31	-0.23	-8.92	-18	-17	-25	-35	-20	-16	-12
NOPAT Margin	-4.00%	-4.58%	-0.46%	-21.49%	-67.06%	-89.60%	-350.40%	-2,318.09%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-3.63%	-3.06%	-2.42%	-4.65%	-23.98%	-31.40%	-22.88%	-54.36%	68.68%	126.10%	-178.92%
Return On Investment Capital (ROIC_SIMPLE)	-2.84%	-3.12%	-	-	-	-19.87%	-	-	-	-14.91%	-
Cost of Revenue to Revenue	10.62%	9.55%	12.30%	6.72%	5.60%	3.56%	1.67%	2.41%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	86.80%	88.51%	80.75%	114.22%	178.91%	212.31%	558.28%	3,126.87%	0.00%	0.00%	0.00%
R&D to Revenue	8.29%	8.48%	7.60%	9.76%	11.29%	12.13%	40.62%	282.29%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	95.09%	96.99%	88.35%	123.98%	190.19%	224.44%	598.90%	3,409.16%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-3.00	-3.30	-0.33	-13	-26	-25	-35	-50	-28	-23	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.18	-2.63	0.71	-12	-25	-25	-34	-48	-26	-21	-15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	10.21	13.71	16.91	19.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	13.22	17.76	21.83	25.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.89	5.99	9.14	14.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	90.97	13,225.11	135.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.02
Enterprise Value to Revenue (EV/Rev)	3.55	5.55	8.66	13.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.15	-2.98	-6.11	-10.95
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.44	-4.33	-8.84
Financial Leverage	-1.02	-1.11	-1.07	-0.99	-1.89	-1.09	-1.05	-0.78	1.87	0.31	-0.11
Leverage Ratio	2.20	2.04	1.96	1.68	7.67	4.47	3.57	2.57	21.20	6.66	4.74
Compound Leverage Factor	3.55	3.06	15.17	1.89	8.03	5.18	3.68	3.33	23.50	7.91	5.61
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.13%	12.71%	150.56%	119.55%	110.05%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.13%	12.71%	27.18%	34.83%	21.24%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	123.38%	84.72%	88.80%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.04%	0.03%	0.01%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	99.94%	83.83%	87.26%	-50.57%	-19.56%	-10.05%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.16	-0.19	-1.28	-1.42	-1.46
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	1.02	1.28	-0.14	-0.36	-0.32
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.05	-1.01	-1.18
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.22	-0.25	-1.65	-1.87	-1.97
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	1.39	1.69	-0.19	-0.48	-0.43
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.35	-1.33	-1.59
Altman Z-Score	-0.10	1.54	3.59	3.26	0.00	0.00	0.00	0.00	0.00	0.00	-4.01
Noncontrolling Interest Sharing Ratio	0.00%	0.03%	0.03%	0.02%	0.01%	0.09%	0.06%	0.04%	0.06%	0.02%	0.01%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.73	2.75	2.97	2.82	2.85	3.64	3.19	3.32	1.38	1.81	2.73
Quick Ratio	2.12	2.21	2.41	2.35	2.33	3.18	2.95	3.15	1.27	1.73	2.57
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-20	-31	-4.29	-33	12	15	-11	80	36	31
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-8.98	-7.31	-10.97	-1.58	-12.83	4.92	7.37	-0.74	24.57	10.95	8.63
Operating Cash Flow to Interest Expense	-3.68	2.91	-2.44	-6.70	-11.46	-11.91	-19.33	-2.08	-9.28	-4.72	-1.91
Operating Cash Flow Less CapEx to Interest Expense	-3.68	2.91	-2.44	-6.70	-11.46	-11.91	-19.33	-2.08	-9.28	-4.72	-1.91
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.16	1.03	0.76	0.53	0.36	0.19	0.05	0.01	0.00	0.00	0.00
Accounts Receivable Turnover	6.05	7.32	6.38	5.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	1.20	1.00	1.04	0.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	466.87	325.85	247.38	158.71	84.31	39.27	11.02	3.09	0.00	0.00	0.00
Accounts Payable Turnover	1.38	1.63	1.05	0.47	0.16	0.09	0.02	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	60.32	49.86	57.25	67.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	305.24	366.48	349.74	525.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	265.06	224.12	346.42	769.21	2,233.78	4,168.38	18,777.22	96,846.67	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	100.51	192.22	60.57	-175.96	-2,233.78	-4,168.38	-18,777.22	-96,846.67	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	7.59	0.07	8.86	-1.09	-10	-17	-22	3.53	-25	12	17
Invested Capital Turnover	-137.96	-19.55	-21.28	78.02	-3.08	-9.75	-3.76	0.10	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	18	17	31	-4.63	15	-29	-39	-23	-100	-52	-43
Enterprise Value (EV)	690	939	1,197	1,280	0.00	0.00	0.00	0.00	0.00	0.00	329
Market Capitalization	757	1,013	1,263	1,351	0.00	0.00	0.00	0.00	0.00	0.00	300
Book Value per Share	$0.77	$0.77	$0.78	$0.73	$0.87	$0.98	$1.23	$1.86	($0.59)	($0.34)	($0.21)
Tangible Book Value per Share	$0.59	$0.59	$0.60	$0.56	$0.68	$0.79	$1.04	$1.65	($0.85)	($0.61)	($0.49)
Total Capital	74	74	75	70	78	88	131	164	75	108	124
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	21	21	114	129	136
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	93	92	110
Net Debt	-66	-74	-66	-71	-89	-105	-132	-140	13	33	30
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	22	12	19	9.79	-0.56	-7.76	-14	-20	-50	-14	-8.47
Debt-free Net Working Capital (DFNWC)	88	85	84	81	88	97	139	141	51	83	98
Net Working Capital (NWC)	88	85	84	81	88	97	118	120	30	45	72
Net Nonoperating Expense (NNE)	2.82	2.74	2.40	4.90	9.12	11	12	30	11	11	8.27
Net Nonoperating Obligations (NNO)	-66	-74	-66	-71	-89	-105	-132	-140	13	33	30
Total Depreciation and Amortization (D&A)	0.83	0.67	1.04	0.44	0.54	-0.02	0.93	1.19	2.46	2.49	2.32
Debt-free, Cash-free Net Working Capital to Revenue	11.23%	6.86%	13.51%	10.28%	-1.02%	-27.77%	-162.06%	-1,332.29%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	45.42%	50.48%	61.14%	85.31%	160.00%	348.13%	1,637.93%	9,396.99%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	45.42%	50.48%	61.14%	85.31%	160.00%	348.13%	1,388.97%	8,003.21%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.05)	($0.04)	($0.03)	($0.14)	($0.30)	($0.28)	($0.41)	($0.83)	($0.48)	($0.44)	($0.33)
Adjusted Weighted Average Basic Shares Outstanding	96.60M	95.14M	96.30M	96.15M	91.69M	80.17M	89.38M	77.25M	63.89M	60.09M	60.20M
Adjusted Diluted Earnings per Share	($0.05)	($0.04)	($0.03)	($0.14)	($0.30)	($0.28)	($0.41)	($0.83)	($0.48)	($0.44)	($0.33)
Adjusted Weighted Average Diluted Shares Outstanding	96.60M	95.14M	96.30M	96.15M	91.69M	80.17M	89.38M	77.25M	63.89M	60.09M	60.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	96.74M	96.63M	96.36M	96.27M	96.12M	90.58M	89.81M	89.37M	76.77M	64.48M	61.78M
Normalized Net Operating Profit after Tax (NOPAT)	-2.10	-2.31	-0.23	-8.92	-18	-17	-25	-35	-20	-16	-12
Normalized NOPAT Margin	-4.00%	-4.58%	-0.46%	-21.49%	-67.06%	-89.60%	-350.40%	-2,318.09%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-9.22%	-9.84%	-5.07%	-34.53%	-100.26%	-148.49%	-515.90%	-4,300.94%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.34	-1.22	-0.12	-4.69	-10.04	-10.58	-17.75	-3.21	-8.68	-7.08	-4.76
NOPAT to Interest Expense	-0.94	-0.85	-0.08	-3.28	-7.03	-7.40	-12.43	-2.25	-6.08	-4.95	-3.33
EBIT Less CapEx to Interest Expense	-1.34	-1.22	-0.12	-4.69	-10.04	-10.58	-17.75	-3.21	-8.68	-7.08	-4.76
NOPAT Less CapEx to Interest Expense	-0.94	-0.85	-0.08	-3.28	-7.03	-7.40	-12.43	-2.25	-6.08	-4.95	-3.33
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Avadel Pharmaceuticals' Financials

When does Avadel Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Avadel Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Avadel Pharmaceuticals' net income changed over the last 2 years?

Avadel Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$48.83 million in 2024, falling from -$137.46 million in 2022. The previous period was -$160.28 million in 2023. Check out Avadel Pharmaceuticals' forecast to explore projected trends and price targets.

What is Avadel Pharmaceuticals's operating income?

Avadel Pharmaceuticals's total operating income in 2024 was -$42.40 million, based on the following breakdown:

Total Gross Profit: $153.84 million
Total Operating Expenses: $196.24 million

How has Avadel Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Avadel Pharmaceuticals' total revenue changed from $0.00 in 2022 to $169.12 million in 2024, a change of 16,911,700,000.0%.

How much debt does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals' total liabilities were at $90.39 million at the end of 2024, a 17.4% increase from 2023, and a 41.3% decrease since 2022.

How much cash does Avadel Pharmaceuticals have?

In the past 2 years, Avadel Pharmaceuticals' cash and equivalents has ranged from $31.17 million in 2023 to $73.98 million in 2022, and is currently $51.37 million as of their latest financial filing in 2024.

How has Avadel Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Avadel Pharmaceuticals' book value per share changed from -0.34 in 2022 to 0.77 in 2024, a change of -323.8%.

Related Companies

This page (NASDAQ:AVDL) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avadel Pharmaceuticals (AVDL) Financials

Frequently Asked Questions About Avadel Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avadel Pharmaceuticals (AVDL) Financials

Annual Income Statements for Avadel Pharmaceuticals

Quarterly Income Statements for Avadel Pharmaceuticals

Annual Cash Flow Statements for Avadel Pharmaceuticals

Quarterly Cash Flow Statements for Avadel Pharmaceuticals

Annual Balance Sheets for Avadel Pharmaceuticals

Quarterly Balance Sheets for Avadel Pharmaceuticals

Annual Metrics And Ratios for Avadel Pharmaceuticals

Quarterly Metrics And Ratios for Avadel Pharmaceuticals

Frequently Asked Questions About Avadel Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools